For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announcedDivi's Laboratories Q4 Results: Divi's Laboratories announced strong financial results for the March quarter. Net profit rose 13% to Rs 751...
Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
Positive Breakout: These 8 stocks cross above their 200 DMAsAs long as the stock is priced above the 200-day SMA on the daily timeframe, it is generally considered to be in an overall uptrend.
FIIs bought 120 Indian stocks in Q4 amid Rs 1.3 lakh crore exodus. What's special about them?Despite a significant Rs 1.3 lakh cr exodus in Q4, Foreign Institutional Investors selectively increased stakes in 120 Indian stocks. These...
Saurabh Mukherjea has moved half his personal portfolio out of India; here's whySaurabh Mukherjea, founder of Marcellus Investment Managers, has shifted his personal portfolio to a 50-50 split between Indian and global ...
Narendra Solanki sees limited IT growth, bets on rural and pharma playsInvestors are becoming selective, focusing on earnings visibility and strong balance sheets. Opportunities are emerging in sectors like IT,...
Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
Sell Divi's Laboratories, target price Rs 4,500: ICICI SecuritiesICICI Securities recommends a sell on Divi's Laboratories with a target price of Rs 4,500 despite recent quarterly growth. Management remai...
Divis Labs shares 0.64% as NiftyA total of 2,625 shares changed hands on the counter till time (IST).
Divis Labs shares 0.2% as Nifty gainsA total of 2,219 shares changed hands on the counter till 01:18PM (IST).
Share price of Divis Labs falls as Sensex gains 208.32 pointsPromoters held 51.9 per cent stake in the company as of 30-Jun-2024, while FII and DII ownership stood at 16.16 per cent and 13.1 per cent,...
Divis Labs shares rise 0.28% as Sensex climbsA total of 2,157 shares changed hands on the counter till 12:27PM (IST)
Buy Divi's Laboratories, target price Rs 3742: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 98115.86 Crore) operating in Pharmace...
Buy Divi's Laboratories, target price Rs 3762: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 99034.38 Crore) operating in Pharmace...